BioSpace News Archive

NeuBase Therapeutics, Inc., a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, at a price to the public of $5.00 per share, generating gross proceeds of $46.0 million before deducting the underwriting discounts and commissions and offering expenses payable by NeuBase.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced an updated development strategy for AT-1501 in renal transplantation.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Mark Shearman, Ph.D., Chief Scientific Officer,

Current Senior Advisor at McKinsey & Co. with strong expertise in global marketing and brand building

Bioceres Crop Solutions Corp., a fully integrated global provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced that it will take part in the Nasdaq Stock Market’s bell-ringing ceremony on April 27, 2021 in celebration of Bioceres’ new listing on the Nasdaq Global Select Market.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, May 10, 2021 to discuss its first quarter operating results. Management will also provide a brief update on the business.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that the Company will release financial results for the first quarter of 2021 on Thursday, May 13, 2021, before the market opens.

First Quarter 2021 Highlights Product revenue increased 10.9% to $299.0 million, or 9.5% on a constant currency basis; GAAP net income per diluted share was $0.92; and Non-GAAP net income per diluted share was $0.90.

HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National Institute of Health and Care Excellence (NICE) has renewed its support for the use of its AI-powered HeartFlow® FFRct Analysis to fight coronary heart disease (CHD), one of the leading causes of death in the UK.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program for the development of a Melanoma antitumor targeting medicine